These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 17883283)

  • 21. Vitamin D, vitamin D receptor and the importance of its activation in patients with chronic kidney disease.
    Bover J; Egido J; Fernández-Giráldez E; Praga M; Solozábal-Campos C; Torregrosa JV; Martínez-Castelao A
    Nefrologia; 2015; 35(1):28-41. PubMed ID: 25611831
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential effects of vitamin D receptor activators on aortic calcification and pulse wave velocity in uraemic rats.
    Noonan W; Koch K; Nakane M; Ma J; Dixon D; Bolin A; Reinhart G
    Nephrol Dial Transplant; 2008 Dec; 23(12):3824-30. PubMed ID: 18644798
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study.
    Ketteler M; Martin KJ; Cozzolino M; Goldsmith D; Sharma A; Khan S; Dumas E; Amdahl M; Marx S; Audhya P
    Nephrol Dial Transplant; 2012 May; 27(5):1942-9. PubMed ID: 21931122
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [New Active vitamin D analogs and calcimimetics to control hyperparathyroidism in chronic renal failure].
    Akiba T
    Clin Calcium; 2007 May; 17(5):767-71. PubMed ID: 17471008
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Paricalcitol - a selective vitamin D receptor activator for secondary hyperparathyroidism in patients with chronic kidney disease].
    Matuszkiewicz-Rowińska J; Żebrowski P
    Wiad Lek; 2016; 69(5):756-759. PubMed ID: 28033603
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interventions for metabolic bone disease in children with chronic kidney disease.
    Hahn D; Hodson EM; Craig JC
    Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD008327. PubMed ID: 26561037
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The pleiotropic effects of paricalcitol: Beyond bone-mineral metabolism.
    Egido J; Martínez-Castelao A; Bover J; Praga M; Torregrosa JV; Fernández-Giráldez E; Solozábal C
    Nefrologia; 2016; 36(1):10-8. PubMed ID: 26705959
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Secondary Hyperparathyroidism: Pathogenesis and Latest Treatment.
    Mizobuchi M; Ogata H; Koiwa F
    Ther Apher Dial; 2019 Aug; 23(4):309-318. PubMed ID: 30411503
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment of secondary hyperparathyroidism in dialysis patients].
    Di Luca M
    G Ital Nefrol; 2009; 26 Suppl 49():S36-48. PubMed ID: 19941277
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Parathyroid interventions: final one piece in the management of uremic SHPT patients].
    Uemura K; Kakuta T
    Clin Calcium; 2010 Jul; 20(7):1104-10. PubMed ID: 20585190
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vitamin D receptor activation and survival in chronic kidney disease.
    Kovesdy CP; Kalantar-Zadeh K
    Kidney Int; 2008 Jun; 73(12):1355-63. PubMed ID: 18288097
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Secondary hyperparathyroidism in chronic dialysis patients: results of the Italian FARO survey on treatment and mortality.
    Brancaccio D; Cozzolino M; Cannella G; Messa P; Bonomini M; Cancarini G; Caruso MR; Cascone C; Costanzo AM; di Luzio Paparatti U; Mazzaferro S;
    Blood Purif; 2011; 32(2):124-32. PubMed ID: 21625082
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New therapies: calcimimetics, phosphate binders and vitamin D receptor activators.
    Cannata-Andía JB; Rodriguez-García M; Román-García P; Tuñón-le Poultel D; López-Hernández F; Rodríguez-Puyol D
    Pediatr Nephrol; 2010 Apr; 25(4):609-16. PubMed ID: 20151157
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Prevention and treatment of secondary hyperparathyroidism in non-dialyzed patients with stage 3-5 chronic kidney diease].
    Cozzolino M; Olivi L; Voli E; Ciceri P; Brancaccio D
    G Ital Nefrol; 2009; 26 Suppl 49():S30-5. PubMed ID: 19941276
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of vitamin D in cardiovascular disease.
    Verhave G; Siegert CE
    Neth J Med; 2010 Mar; 68(3):113-8. PubMed ID: 20308705
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease.
    Andress DL; Coyne DW; Kalantar-Zadeh K; Molitch ME; Zangeneh F; Sprague SM
    Endocr Pract; 2008; 14(1):18-27. PubMed ID: 18238737
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathogenesis and treatment of secondary hyperparathyroidism in dialysis patients: the role of paricalcitol.
    Cozzolino M; Galassi A; Gallieni M; Brancaccio D
    Curr Vasc Pharmacol; 2008 Apr; 6(2):148-53. PubMed ID: 18393917
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism in stage 5 chronic kidney disease.
    Quarles LD
    Kidney Int Suppl; 2005 Jul; (96):S24-8. PubMed ID: 15954947
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New acquisitions in therapy of secondary hyperparathyroidism in chronic kidney disease and peritoneal dialysis patients: role of vitamin D receptor activators.
    Brancaccio D; Cozzolino M; Pasho S; Fallabrino G; Olivi L; Gallieni M
    Contrib Nephrol; 2009; 163():219-226. PubMed ID: 19494617
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Utilization of alfacalcidol and active vitamin D analogs in chronic kidney disease].
    Ureña-Torres PA; Cozzolino M; Bover J
    Nephrol Ther; 2018 Jun; 14(4):189-200. PubMed ID: 29545131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.